



IRB CONTINUING REVIEW APPROVAL

December 10, 2020

Dear David C Dale:

On 12/10/2020, University of Washington IRB Committee D reviewed the following application:

Type of Review:	Continuing Review
Title of Study:	Severe Chronic Neutropenia International Registry
Investigator:	David C Dale
STUDY ID	STUDY00000996
CR ID:	CR00003966
Funding:	Name: Amgen, Inc., Grant Office ID: A98740, Funding Source ID: n/a; Name: National Institutes of Health (NIH), Grant Office ID: A94469, Funding Source ID: 5R 24AI049393-11
IND, IDE, or HDE:	None

IRB Approval

Under FWA #00006878, the IRB renewed approval for your activity from 12/10/2020 to 12/9/2021.

- COVID NOTE: Researchers must comply with current infection control requirements and complete a self-assessment that activities fit within allowable research as described on the [HSD website](#).
- Your application qualified for expedited review ("minimal risk"; Category 7).
- This approval applies only to the activities described in your application (including any references to specific grant sections). It does not include other activities that may be described in your grant or contract.

Thank you for your commitment to ethical and responsible research. We wish you great success!

Sincerely,

Leah M. Miller, PhD
Team Operations Lead, IRB-D and Team D
lemiller@uw.edu
(206) 543-2977